Patients Descriptions | Events/Total (%) | Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p |
Age group < 35 years 35–50 years > 50 years | 23/84 (27.3) 138/756 (18.2) 254/1177 (21.5) | 1 (Reference) 0.627 (0.403–0.974) 0.826 (0.539–1.266) | .038 .381 | 1 (Reference) 1.218 (.747-1.986) 1.466 (.836 − 2.570) | .429 .182 |
BMI < 25 ≥ 25 | 73/373 (19.5) 342/1644 (20.8) | 1.059 (0.823–1.364) | .656 | | |
Menopause Age (mean) Events 48.36 years None Events 48.30 years | 260/2017 (12.8) | 1.010 (0.984–1.037) | .470 | | . |
Menstruation Age (mean) Events 13.04 years None Events 13.17 years | 415/2017(20.5) | 0.915 (0.850–0.986) | .019 | .959 (.851 − 1.080) | .486 |
Menstruation situation Premenopause Postmenopause | 149/787 (18.9) 260/1217 (21.3) | 1.221 (.998-1.495) | .052 | 1.053 (.746-1.487) | .769 |
Number of births No birth 1–2 birth 3 and more | 38/162 (23.4) 255/1320 (19.3) 115/520 (22.1) | 1 (Reference) .834 (.593-1.173) .928 (.643-1.339) | .435 .296 .690 | | |
Family History Positive Negative | 115/632 (18.1) 300/1385 (21.6) | .850 (.685-1.054) | .138 | | |
Breast-feeding Positive Negative | 229/1192 (19.2) 186/825 (22.5) | .869 (.716-1.055) | .156 | | |
Breast site Left Right Bilateral | 205/1013 (20.2) 186/935 (19.8) 24/69 (34.7) | 1 (Reference) .000 (.000-6.51) < .001 (.000-2.31) | .939 .935 | | |
Location Unilateral Metacron Sencron | 391/1948 (20) 17/46 (36.9) 7/23 (30.4) | 1 (Reference) 1.590 (.978-2.586) 1.770 (.838-3.739) | .061 .135 | | |
Tumor Quadrant Inner Outer Periareolar Multifokal | 80/402 (19.9) 234/1205 (19.4) 54/259 (20.8) 47/150 (31.3) | 1 (Reference) .994 (.771-1.281) 1.081 (.766-1.527) 1.819 (1.269–2.608) | .962 .657 .001 | 1 (Reference) .924 (.697-1.225) .713 (.479-1.062) .721 (.466-1.117) | .583 .096 .143 |
Histopathologic Type IDC ILC Other | 344/1652 (20.8) 26/122 (21.3) 45/243(18.5) | 1 (Reference) .954 (.640-1.422) .864 (.633-1.179) | .646 .817 .356 | | |
Surgical Type BCS MRM No surgery | 122/1016 (12) 226/930 (24.3) 67/71(94.3) | 1 (Reference) 1.978 (1.586–2.466) 27.941(20.296–38.465) | < .001 < .001 | 1 (Reference) .834 (.634 − 1.090) 1.444 (.676-3.087) | .184 .343 |
Axillary Surgery Type SLND AD No axillary surgery | 37/451(8.2) 304/1477(20.5) 74/89(83.1) | 1 (Reference) 2.210 (1.569–3.111) 21.759 (14.573–32.487) | < .001 < .001 | 1 (Reference) .645(.427-.975) 1.056 (.455-2.448) | .037 .900 |
Stage I II III IV | 23/415 (5.54) 96/881 (10.8) 158/583 (27.1) 138/138 (100) | 1 (Reference) 1.960 (1.244–3.090) 5.447 (3.517–8.436) 95.570 (60.478-151.023) | < .001 .004 < .001 < .001 | | |
T stage T1 T2 T3 T4 | 67/670 (10) 220/1048 (20.9) 38/155 (24.5) 89/143 (62.2) | 1 (Reference) 2.207 (1.679–2.902) 2.438 (1.637–3.631) 11.090 (8.050-15.279) | < .001 < .001 < .001 | 1 (Reference) 1.426 (1.037–1.962) 1.579 (1.012–2.464) 1.794 (1.053–3.057) | .029 .044 .032 |
Positive Axillary Node Count 0 1–3 4–9 ≥10 | 78/861 (9.06) 80/531 (15.07) 145/402 (36.07) 111/222 (50) | 1 (Reference) 1.668 (1.221–2.278) 5.000 (3.795–6.587) 7.384 (5.524–9.870) | .001 < .001 < .001 | 1 (Reference) .811 (.561-1.171) 1.338 (.928-1.929) 1.644 (1.116–2.423) | .263 .119 .012 |
Metastasis site None Bone Lung Liver Brain Multiple organs | 25/1627 (1.53) 142/142 (100) 25/25 (100) 15/15 (100) 21/21 (100) 185/185 (100) | 1 (Reference) 156.760 (102.099-240.686) 139.613 (79.878-244.018) 171.002 (89.530-326.613) 173.699 (96.477-312.733) 164.232 (107.535-250.822) | < .001 < .001 < .001 < .001 < .001 | 1 (Reference) 158.568(100.278.250.742) 131.993 (72.208-241.278) 133.403 (64.540-275.738) 129.981 (68.258-247.517) 126.654 (79.530-201.699) | < .001 < .001 < .001 < .001 < .001 |
Skin infiltration Positive Negative | 80/152 (52.6) 335/1865 (18) | 4.664 (3.642–5.974) | < .001 | 1.249 (.783-1.991) | .351 |
Surgical margin Positive Negative | 69/367 (18.8) 346/1650 (21) | 1.004 (.775-1.301) | .975 | | |
Grade 1 2 3 | 23/304 (7.5) 155/987 (15.7) 237/726 (32.6) | 1 (Reference) 2.290 (1.478–3.550) 5.417 (3.528–8.317) | < .001 < .001 | 1 (Reference) .712 (.424-1.195) 1.017 (.595-1.739) | .198 .950 |
Mitotic index 1 2 3 | 97/775 (12.5) 98/637 (15.3) 218/591 (36.8) | 1 (Reference) 1.546 (1.164–2.053) 4.303 (3.369–5.497) | .003 < .001 | 1 (Reference) 1.033 (.734-1.455) .996 (.726-1.367) | .851 .982 |
ER receptor Positive Negative | 300/1598 (18.7) 115/419 (27.4) | .648 (.523-.804) | < .001 | .838 (.403 − 1.350) | .324 |
PR receptor Positive Negative | 240/1337 (18) 175/680 (25.7) | .640 (.526-.777) | < .001 | 1.029 (.769-1.376) | .847 |
Ki67 <15 ≥15 | 204/1130 (18) 210/885 (23.7) | 1.758 (1.443–2.143) | < .001 | 1.062 (.811-1.389) | .662 |
HER2 Positive Negative | 125/478 (26.1) 290/1539(18.8) | 1.646 (1.333–2.032) | < .001 | 1.077 (.730 − 1.590) | .708 |
EIC Positive Negative | 96/334 (28.7) 319/1683 (18.9) | 1.646 (1.310–2.069) | < .001 | 1.175 (.895-1.542) | .247 |
LVI Positive Negative | 211/954 (22.1) 204/1063 (19.1) | 1.190 (.981-1.443) | .077 | 1.077 (.832-1.394) | .574 |
PNI Positive Negative | 103/437 (23.5) 312/1580(19.7) | 1.145 (.917-1.431) | .233 | | |
Chemotherapy None Neoadjuvant Adjuvant | 40/324 (12.3) 78/235 (33.1) 297/1458 (20.3) | 1 (Reference) 3.202 (2.186–4.690) 1.553 (1.116–2.161) | < .001 < .001 | 1 (Reference) 1.137 (.699-1.851) .840 (.563-1.252) | .604 .301 |
Chemotherapy Protocol None FAC AC + TXT Other | 40/324 (12.3) 54/166 (32.5) 34/273 (12.4) 279/1235 (22.5) | 1 (Reference) 1.858 (1.255–2.750) 1.429 (.569-3.592) 1.694 (1.247–2.301) | .002 .447 .001 | | |
Radiotherapy Positive Negative | 295/1757 (16.7) 120/260 (46.1) | .302 (.244-.374) | < .001 | .470 (.352-.626) | < .001 |
Radiotherapy Type None Breast alone Locoregional | 120/260 (46.1) 44/587 (7.5) 51/1170(4.3) | 1 (Reference) .127 (.090-.179) .389 (.312-.484) | < .001 < .001 | | |
Tamoxifen period No TMX TMX ≤ 5 years TMX > 5 years | 130/652 (19.9) 9/107 (8.4) | 1 (Reference) .769 (.623-.949) .283 (.146-.551) | .014 < .001 | 1 (Reference) 1.022 (.733-1.425) .425 (.196-.922) | .896 .030 |
AI period No AI AI ≤ 5 years AI > 5 years | 191/937 (20.3) 32/265 (12) | 1 (Reference) .812 (.664-.992) .404 (.278-.589) | .042 < .001 | 1 (Reference) .861 (.643-1.154) .817 (.505-1.319) | .317 .408 |
LHRH None LHRH ≤2 years >2 years | 8/35 (22.8) 57/343 (16.6) | 1 (Reference) 1.242 (.616-2.504) .754 (.570-.998) | .544 .048 | 1 (Reference) 2.426 (1.057–5.568) 1.225 (.798 − 1.880) | .037 .353 |
Subtyping 2 HER2 enriched TNBC Luminal A Luminal B | 51/142 (35.9) 51/236 (21.6) 182/952 (19.1) 131/688 (19.0) | 1 (Reference) .479 (.325-.707) .380 (.278-.520) .488 (.353-.675) | < .001 < .001 < .001 | 1 (Reference) .794 (.438-1.438) .891 (.336-2.362) 1.157 (.543-2.463) | .447 .817 .706 |
HER2 enriched could get Herceptine HER2 enriched did not get Herceptine | 40/120 (33.3) 11/22 (50) | 1.515 (.777-2.954) | .223 | | |